Drug/Small Molecule:
ketoconazole

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with ketoconazole that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105170

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all ketoconazole variant annotations

Gene ? Variant?
(142)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C19 *1A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *1B N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2B N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2C N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *8 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *11 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *13 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *14 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *15 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *16 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *18 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *19 N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *1A N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *3A N/A N/A N/A
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 142
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • 2%
  • Ketocanazole
  • Ketoconazol
  • Ketoconazol [INN-Spanish]
  • Ketoconazole [Usan:Ban:Inn:Jan]
  • Ketoconazolum [INN-Latin]
  • ketoconazole
Trade Names
  • Extina
  • Fungarest
  • Fungoral
  • Ketoderm
  • Ketoisdin
  • Ketozole
  • Nizoral
  • Nizoral Cream
  • Nizoral Shampoo
  • Nizoral a-D
  • Nizoral a-D Shampoo
  • Orifungal
  • Orifungal M
  • Panfungol
  • Sebazole
Brand Mixture Names

PharmGKB Accession Id:
PA450146

Description

Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients.

Source: Drug Bank

Indication

For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Ketoconazole interacts with 14-alpha demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone.

Source: Drug Bank

Pharmacology

Ketoconazole, like clotrimazole, fluconazole, itraconazole, and miconazole, is an imidazole antifungal agent.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.|Take with food.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic

Source: Drug Bank

Protein Binding

99% (in vitro, plasma protein binding)

Source: Drug Bank

Absorption

Moderate

Source: Drug Bank

Half-Life

2 hours

Source: Drug Bank

Toxicity

Hepatotoxicity, LD 50=86 mg/kg (orally in rat)

Source: Drug Bank

Chemical Properties

Chemical Formula

C26H28Cl2N4O4

Source: Drug Bank

Isomeric SMILES

CC(=O)N1CCN(CC1)c2ccc(cc2)OC[C@@H]3CO[C@@](O3)(Cn4ccnc4)c5ccc(cc5Cl)Cl

Source: OpenEye

Canonical SMILES

CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1

Source: Drug Bank

Average Molecular Weight

531.431

Source: Drug Bank

Monoisotopic Molecular Weight

530.148760818

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
CYP51A1 (source: Drug Bank)

Drug Interactions

Drug Description
ketoconazole The antifungal increases the effect of alfuzosin (source: Drug Bank)
ketoconazole This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
ketoconazole This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of the tricyclic (source: Drug Bank)
ketoconazole Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole This CYP3A4 inhibitor increases the effect and toxicity of aprepitant (source: Drug Bank)
ketoconazole The imidazole increases the effect of aripiprazole (source: Drug Bank)
ketoconazole The imidazole increases the effect of aripiprazole (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
ketoconazole Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
ketoconazole This imidazole increases the effect and toxicity of bosentan (source: Drug Bank)
ketoconazole This imidazole increases the effect and toxicity of bosentan (source: Drug Bank)
ketoconazole Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole The imidazole increases levels/effect of budesonide (source: Drug Bank)
ketoconazole The imidazole increases levels/effect of budesonide (source: Drug Bank)
ketoconazole The macrolide increases the effect and toxicity of buspirone (source: Drug Bank)
ketoconazole The macrolide increases the effect and toxicity of buspirone (source: Drug Bank)
ketoconazole The antacid decreases the effect of the imidazole (source: Drug Bank)
ketoconazole The antacid decreases the effect of the imidazole (source: Drug Bank)
ketoconazole The imidazole increases the effect of carbamazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of carbamazepine (source: Drug Bank)
ketoconazole Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
ketoconazole Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole Increased effects/toxicity of ciclesonide (source: Drug Bank)
ketoconazole The imidazole increases the effect of cilostazol (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of cinacalcet (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of immunosuppressant (source: Drug Bank)
ketoconazole The imidazole increases the effect of immunosuppressant (source: Drug Bank)
ketoconazole Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism (source: Drug Bank)
ketoconazole This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole Possible ergotism and severe ischemia with this combination (source: Drug Bank)
ketoconazole Possible ergotism and severe ischemia with this combination (source: Drug Bank)
ketoconazole The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
ketoconazole Ketoconazole may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
ketoconazole This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
ketoconazole This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
ketoconazole This CYP3A4 inhibitor increases the effect and toxicity of eplerenone (source: Drug Bank)
ketoconazole Possible ergotism and severe ischemia with this combination (source: Drug Bank)
ketoconazole Possible ergotism and severe ischemia with this combination (source: Drug Bank)
ketoconazole This CYP3A4 inhibitor increases levels/toxicity of erlotinib (source: Drug Bank)
ketoconazole This CYP3A4 inhibitor increases levels/toxicity of erlotinib (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
ketoconazole This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole Ketoconazole increases the effect and toxicity of galantamine (source: Drug Bank)
ketoconazole Ketoconazole increases the effect and toxicity of galantamine (source: Drug Bank)
ketoconazole This CYP3A4 inhibitor increases levels/toxicity of gefitinib (source: Drug Bank)
ketoconazole This CYP3A4 inhibitor increases levels/toxicity of gefitinib (source: Drug Bank)
ketoconazole Ketoconazole increases the effect of rosiglitazone (source: Drug Bank)
ketoconazole Ketoconazole increases the effect of rosiglitazone (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of haloperidol (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of haloperidol (source: Drug Bank)
ketoconazole The imidazole increases the levels of imatinib (source: Drug Bank)
ketoconazole The imidazole increases the levels of imatinib (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of the tricyclic (source: Drug Bank)
ketoconazole Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole increases the efefct of indinavir (source: Drug Bank)
ketoconazole Ketoconazole increases the efefct of indinavir (source: Drug Bank)
ketoconazole Isoniazid decreases the effect of ketoconazole (source: Drug Bank)
ketoconazole Isoniazid decreases the effect of ketoconazole (source: Drug Bank)
acenocoumarol The imidazole increases the effect of the anticoagulant (source: Drug Bank)
acenocoumarol Ketoconazole may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank)
alfentanil The imidazole increases the effect and toxicity of alfentanil (source: Drug Bank)
alfentanil The imidazole increases the effect and toxicity of alfentanil (source: Drug Bank)
alfuzosin The antifungal increases the effect of alfuzosin (source: Drug Bank)
alfuzosin The antifungal increases the effect of alfuzosin (source: Drug Bank)
almotriptan This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
almotriptan This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
alprazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
alprazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
aluminium The antacid decreases the effect of the imidazole (source: Drug Bank)
aluminium The antacid decreases the effect of the imidazole (source: Drug Bank)
amitriptyline The imidazole increases the effect and toxicity of the tricyclic (source: Drug Bank)
amitriptyline Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
anisindione The imidazole increases the effect of the anticoagulant (source: Drug Bank)
anisindione Ketoconazole may increase the anticoagulant effect of anisindione. (source: Drug Bank)
aprepitant This CYP3A4 inhibitor increases the effect and toxicity of aprepitant (source: Drug Bank)
aprepitant This CYP3A4 inhibitor increases the effect and toxicity of aprepitant (source: Drug Bank)
aripiprazole The imidazole increases the effect of aripiprazole (source: Drug Bank)
aripiprazole The imidazole increases the effect of aripiprazole (source: Drug Bank)
astemizole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
astemizole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
atorvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
atorvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
bosentan The imidazole increases the effect and toxicity of bosentan (source: Drug Bank)
bosentan The imidazole increases the effect and toxicity of bosentan (source: Drug Bank)
budesonide The imidazole increases levels/effect of budesonide (source: Drug Bank)
budesonide The imidazole increases levels/effect of budesonide (source: Drug Bank)
buspirone The macrolide increases the effect and toxicity of buspirone (source: Drug Bank)
buspirone The macrolide increases the effect and toxicity of buspirone (source: Drug Bank)
Calcium The antacid decreases the effect of the imidazole (source: Drug Bank)
Calcium The antacid, calcium carbonate, may decrease the effect of ketoconazole by decreasing its absorption. (source: Drug Bank)
carbamazepine The imidazole increases the effect of carbamazepine (source: Drug Bank)
carbamazepine The imidazole increases the effect of carbamazepine (source: Drug Bank)
cerivastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
cerivastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
chlordiazepoxide The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
chlordiazepoxide The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ciclesonide Increased effects/toxicity of ciclesonide (source: Drug Bank)
ciclesonide Increased effects/toxicity of ciclesonide (source: Drug Bank)
cilostazol The imidazole increases the effect of cilostazol (source: Drug Bank)
cilostazol The imidazole increases the effect of cilostazol (source: Drug Bank)
cimetidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
cimetidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
cinacalcet The imidazole increases the effect and toxicity of cinacalcet (source: Drug Bank)
cinacalcet The imidazole increases the effect and toxicity of cinacalcet (source: Drug Bank)
cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
clonazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
clonazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
clorazepate The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
clorazepate The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
cyclosporine The imidazole increases the effect of immunosuppressant (source: Drug Bank)
cyclosporine The imidazole increases the effect of immunosuppressant (source: Drug Bank)
darifenacin This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism (source: Drug Bank)
darifenacin This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism (source: Drug Bank)
diazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
diazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
dicumarol The imidazole increases the effect of the anticoagulant (source: Drug Bank)
dicumarol Ketoconazole may increase the anticoagulant effect of dicumarol. (source: Drug Bank)
dihydroergotamine Possible ergotism and sever ischemia with this combination (source: Drug Bank)
dihydroergotamine Possible ergotism and sever ischemia with this combination (source: Drug Bank)
docetaxel The agent increases the serum levels and toxicity of docetaxel (source: Drug Bank)
docetaxel Ketoconazole may increase the serum levels and toxicity of docetaxel. (source: Drug Bank)
dofetilide This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide (source: Drug Bank)
dofetilide This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide (source: Drug Bank)
eletriptan This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
eletriptan This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan (source: Drug Bank)
eplerenone The imidazole increases the effect and toxicity of eplerenone (source: Drug Bank)
eplerenone The imidazole increases the effect and toxicity of eplerenone (source: Drug Bank)
ergotamine Possible ergotism and sever ischemia with this combination (source: Drug Bank)
ergotamine Possible ergotism and sever ischemia with this combination (source: Drug Bank)
erlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinib (source: Drug Bank)
erlotinib This CYP3A4 inhibitor increases levels/toxicity of erlotinib (source: Drug Bank)
esomeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
esomeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
estazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
estazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
estradiol This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
ethinyl estradiol This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
everolimus The imidazole increases everolimus levels/toxicity (source: Drug Bank)
everolimus The imidazole increases everolimus levels/toxicity (source: Drug Bank)
famotidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
famotidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
fentanyl The imidazole increases levels/toxicity of fentanyl (source: Drug Bank)
flurazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
flurazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
galantamine Ketoconazole increases the effect and toxicity of galantamine (source: Drug Bank)
galantamine Ketoconazole increases the effect and toxicity of galantamine (source: Drug Bank)
gefitinib This CYP3A4 inhibitor increases levels/toxicity of gefitinib (source: Drug Bank)
gefitinib This CYP3A4 inhibitor increases levels/toxicity of gefitinib (source: Drug Bank)
halazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
halazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
haloperidol The imidazole increases the effect and toxicity of haloperidol (source: Drug Bank)
haloperidol The imidazole increases the effect and toxicity of haloperidol (source: Drug Bank)
imatinib The imidazole increases the levels of imatinib (source: Drug Bank)
imatinib The imidazole increases the levels of imatinib (source: Drug Bank)
imipramine The imidazole increases the effect and toxicity of the tricyclic (source: Drug Bank)
imipramine Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
indinavir Ketoconazole increases the effect of indinavir (source: Drug Bank)
indinavir Ketoconazole increases the effect of indinavir (source: Drug Bank)
irinotecan Ketoconazole increases the effect and toxicity of irinotecan (source: Drug Bank)
irinotecan Ketoconazole increases the effect and toxicity of irinotecan (source: Drug Bank)
isoniazid Isoniazid decreases the effect of ketoconazole (source: Drug Bank)
isoniazid Isoniazid decreases the effect of ketoconazole (source: Drug Bank)
lansoprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
lansoprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
lovastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
lovastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
Magnesium The antacid decreases the effect of the imidazole (source: Drug Bank)
Magnesium The antacid decreases the effect of the imidazole (source: Drug Bank)
Magnesium The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption. (source: Drug Bank)
magnesium oxide The antacid decreases the effect of the imidazole (source: Drug Bank)
mestranol This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
mestranol This anti-infectious agent could decrease the effect of the oral contraceptive (source: Drug Bank)
methylprednisolone The imidazole increases the effect and toxicity of the corticosteroid (source: Drug Bank)
methylprednisolone The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone. (source: Drug Bank)
midazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
midazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
nevirapine Nevirapine decreases the effect of ketoconazole (source: Drug Bank)
nevirapine Nevirapine decreases the effect of ketoconazole (source: Drug Bank)
nizatidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
nizatidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
nortriptyline The imidazole increases the effect and toxicity of the tricyclic (source: Drug Bank)
nortriptyline Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
omeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
omeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
pantoprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
pantoprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
pimozide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
pimozide Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
pioglitazone Ketoconazole increases the effect of pioglitazone (source: Drug Bank)
pioglitazone Ketoconazole increases the effect of pioglitazone (source: Drug Bank)
prednisolone The imidazole increases the effect and toxicity of the corticosteroid (source: Drug Bank)
prednisolone The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone. (source: Drug Bank)
prednisone The imidazole increases the effect and toxicity of the corticosteroid (source: Drug Bank)
prednisone The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone. (source: Drug Bank)
quazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
quazepam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
quetiapine Ketoconazole increases the effect/toxicity of quetiapine (source: Drug Bank)
quetiapine Ketoconazole increases the effect/toxicity of quetiapine (source: Drug Bank)
quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank)
quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank)
quinidine The imidazole increases the effect and toxicity of quinidine (source: Drug Bank)
rabeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
rabeprazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ramelteon The imidazole increases the levels/toxicity of ramelteon (source: Drug Bank)
ramelteon The imidazole increases the levels/toxicity of ramelteon (source: Drug Bank)
ranitidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ranitidine The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ranolazine Increased levels of ranolazine - risk of toxicity (source: Drug Bank)
ranolazine Increased levels of ranolazine - risk of toxicity (source: Drug Bank)
rifampin Rifampin dereases the effect of the imidazole (source: Drug Bank)
rifampin Rifampin dereases the effect of the imidazole (source: Drug Bank)
ritonavir The imidazole increases the effect and toxicity of ritonavir (source: Drug Bank)
ritonavir The imidazole increases the effect and toxicity of ritonavir (source: Drug Bank)
rosiglitazone Ketoconazole increases the effect of rosiglitazone (source: Drug Bank)
rosiglitazone Ketoconazole increases the effect of rosiglitazone (source: Drug Bank)
saquinavir The imidazole increases the effect and toxicity of saquinavir (source: Drug Bank)
saquinavir The imidazole increases the effect and toxicity of saquinavir (source: Drug Bank)
sibutramine Ketoconazole increases the levels and toxicity of sibutramine (source: Drug Bank)
sibutramine Ketoconazole increases the levels and toxicity of sibutramine (source: Drug Bank)
sildenafil The imidazole increases the effect and toxicity of sildenafil (source: Drug Bank)
sildenafil The imidazole increases the effect and toxicity of sildenafil (source: Drug Bank)
simvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
simvastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
sirolimus The imidazole increases the effect and toxicity of sirolimus (source: Drug Bank)
sirolimus The imidazole increases the effect and toxicity of sirolimus (source: Drug Bank)
solifenacin This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism (source: Drug Bank)
solifenacin This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism (source: Drug Bank)
sucralfate Sucralfate decreases the absorption of the imidazole (source: Drug Bank)
sucralfate Sucralfate decreases the absorption of the imidazole (source: Drug Bank)
sunitinib Possible increase in sunitinib levels (source: Drug Bank)
sunitinib Possible increase in sunitinib levels (source: Drug Bank)
tacrolimus The imidazole increases the effect of immunosuppressant (source: Drug Bank)
tacrolimus The imidazole increases the effect of immunosuppressant (source: Drug Bank)
tadalafil The imidazole increases tadalafil levels (source: Drug Bank)
tadalafil The imidazole increases tadalafil levels (source: Drug Bank)
terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
tolbutamide Ketoconazole increases the effect and toxicity of tolbutamide (source: Drug Bank)
tolbutamide Ketoconazole increases the effect and toxicity of tolbutamide (source: Drug Bank)
tolterodine The imidazole increases the effect and toxicity of tolterodine (source: Drug Bank)
tolterodine The imidazole increases the effect and toxicity of tolterodine (source: Drug Bank)
trazodone This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
trazodone This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
triazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
triazolam The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
valdecoxib The imidazole increases the effect and toxicity of valdecoxib (source: Drug Bank)
valdecoxib The imidazole increases the effect and toxicity of valdecoxib (source: Drug Bank)
vardenafil The imidazole increases the effect and toxicity of vardenafil (source: Drug Bank)
vardenafil The imidazole increases the effect and toxicity of vardenafil (source: Drug Bank)
vinblastine The imidazole increases the effect and toxicity of vinblastine (source: Drug Bank)
vinblastine The imidazole increases the effect and toxicity of vinblastine (source: Drug Bank)
vincristine The imidazole increases the effect and toxicity of the antineoplasic (source: Drug Bank)
vincristine The imidazole increases the effect and toxicity of the antineoplasic (source: Drug Bank)
warfarin The imidazole increases the effect of the anticoagulant (source: Drug Bank)
warfarin Ketoconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. (source: Drug Bank)
ziprasidone Ketoconazole increases the effect and toxicity of ziprasidone (source: Drug Bank)
ziprasidone Ketoconazole increases the effect and toxicity of ziprasidone (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
ketoconazole Increased risk of myopathy/rhabdomyolysis (source: Drug Bank)
ketoconazole The imidazole increases the effect of benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of benzodiazepine (source: Drug Bank)
ketoconazole Decreases the effect of ketoconazole (source: Drug Bank)
ketoconazole Decreases the effect of ketoconazole (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of the tricyclic (source: Drug Bank)
ketoconazole Ketoconazole, a moderate CYP2D6 inhibitor, may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole Ketoconazole increases the effect of pioglitazone (source: Drug Bank)
ketoconazole Ketoconazole increases the effect of pioglitazone (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of the corticosteroid (source: Drug Bank)
ketoconazole The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone. (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of the corticosteroid (source: Drug Bank)
ketoconazole The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone. (source: Drug Bank)
ketoconazole Ketoconazole increases effect/toxicity of quetiapine (source: Drug Bank)
ketoconazole Ketoconazole increases effect/toxicity of quetiapine (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of quinidine (source: Drug Bank)
ketoconazole The imidazole increases the effect and toxicity of quinidine (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole The proton pump inhibitor decreases the absorption of imidazole (source: Drug Bank)
ketoconazole This imidazole increases levels/toxicity of ramelteon (source: Drug Bank)
ketoconazole This imidazole increases levels/toxicity of ramelteon (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole The anti-H2 decreases the absorption of the imidazole (source: Drug Bank)
ketoconazole Increased levels of ranolazine - risk of toxicity (source: Drug Bank)
ketoconazole Rifampin decreases the effect of the imidazole (source: Drug Bank)
ketoconazole Rifampin decreases the effect of the imidazole (source: Drug Bank)
ketoconazole The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed. (source: Drug Bank)
ketoconazole The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed. (source: Drug Bank)
ketoconazole The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered. (source: Drug Bank)
ketoconazole Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity. (source: Drug Bank)
ketoconazole Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects. (source: Drug Bank)
ketoconazole Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. (source: Drug Bank)
ketoconazole The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
ketoconazole The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Tipranavir may increase the serum concentration of Ketoconazole. (source: Drug Bank)
ketoconazole Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank)
ketoconazole Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank)
ketoconazole The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production. (source: Drug Bank)
ketoconazole The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole This strong CYP3A4 inhibitor increases the effect and toxicity of trazodone (source: Drug Bank)
ketoconazole The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank)
ketoconazole The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated. (source: Drug Bank)
ketoconazole Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)
ketoconazole Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank)

Curated Information ?

EvidenceDisease
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Toxicity

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to ketoconazole: 54

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP4F2. Pharmacogenetics and genomics. 2014. Alvarellos Maria L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies. Clinical pharmacology and therapeutics. 2014. Ke A B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on CYP3A-Mediated Drug-Drug Interactions. Drug metabolism and disposition: the biological fate of chemicals. 2013. Shirasaka Yoshiyuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. European journal of clinical pharmacology. 2013. Fuchs Ines, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012. Cohen Ezra E W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Evaluation of the effects of 18 non-synonymous single-nucleotide polymorphisms of CYP450 2C19 on in vitro drug inhibition potential by a fluorescence-based high-throughput assay. Xenobiotica; the fate of foreign compounds in biological systems. 2011. Wang Huijuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Oswald S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research. Current clinical pharmacology. 2009. Srinivas Nuggehally R. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxidants & redox signaling. 2009. Kuo Macus Tien. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008. Luna-Tortós Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug target identification using side-effect similarity. Science (New York, N.Y.). 2008. Campillos Monica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug metabolism and disposition: the biological fate of chemicals. 2008. Svecova Lucie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008. Uhr Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological research : the official journal of the Italian Pharmacological Society. 2008. Nikisch Georg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clinical pharmacology and therapeutics. 2007. Farid N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007. Mensah-Osman Edith J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2007. Marguerite Véronique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Molecular pharmaceutics. 2007. Collnot Eva-Maria, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Molecular pharmacology. 2006. Duret Cedric, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer research. 2006. Leggas Markos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Impact of P-glycoprotein on clopidogrel absorption. Clinical pharmacology and therapeutics. 2006. Taubert Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert opinion on drug delivery. 2006. Dey Surajit. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Yong Wei Peng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. Annals of the New York Academy of Sciences. 2004. Parker Robert S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical pharmacology. 2004. Ehrhardt Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharmaceutical research. 2004. Hochman Jerome H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. British journal of clinical pharmacology. 2004. Hutchinson Mark R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical pharmacology and therapeutics. 2004. Marzolini Catia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Genetic polymorphisms of the human MDR1 drug transporter. Annual review of pharmacology and toxicology. 2003. Schwab Matthias, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of galantamine. Clinical pharmacokinetics. 2003. Farlow Martin R. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. The Journal of biological chemistry. 2002. Takeshita Akira, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction of common azole antifungals with P glycoprotein. Antimicrobial agents and chemotherapy. 2002. Wang Er-jia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg's archives of pharmacology. 2001. Pauli-Magnus C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of fluvastatin. Clinical pharmacokinetics. 2001. Scripture C D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000. Haritos V S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibitory effect of azole antifungal agents on the glucuronidation of lorazepam using rabbit liver microsomes in vitro. Biological & pharmaceutical bulletin. 2000. Sawamura R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. The Journal of clinical investigation. 1999. Greiner B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. Journal of clinical pharmacology. 1999. Venkatakrishnan K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual review of pharmacology and toxicology. 1999. Ambudkar S V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica; the fate of foreign compounds in biological systems. 1998. Tassaneeyakul W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochimica et biophysica acta. 1997. Litman T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. British journal of clinical pharmacology. 1995. Sampol E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
P-glycoprotein structure and evolutionary homologies. Cytotechnology. 1993. Croop J M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA : the journal of the American Medical Association. 1993. Honig P K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 1992. Maurice M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
http://www.medscape.com/druginfo/monoinfobyid?cid=med&monotype=druginter&monoid=1697&mononame=CLARITHROMYCIN;+TELITHROMYCIN/IXABEPILONE&drugid=5030&drugname=Clarithromycin+Oral&intertype=server. [URL:http://www.medscape.com/druginfo/monoinfobyid?cid=med&monotype=druginter&monoid=1697&mononame=CLARITHROMYCIN;+TELITHROMYCIN/IXABEPILONE&drugid=5030&drugname=Clarithromycin+Oral&intertype=server]

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0145-0003-05
DrugBank:
DB01026
PDB:
KTN
ChEBI:
48339
KEGG Drug:
D00351
PubChem Compound:
47576
PubChem Substance:
186839
IUPHAR Ligand:
2568
Drugs Product Database (DPD):
2237235
BindingDB:
31768
HET:
KTN
Therapeutic Targets Database:
DAP000630

Clinical Trials

These are trials that mention ketoconazole and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.